Abstract Phosphatidylinositol transfer proteins (PITPs) bind phosphatidylinositol (PtdIns) and phosphatidylcholine and play diverse roles in coordinating lipid metabolism/ signaling with intracellular functions. The underlying mechanisms remain unclear. Genetic ablation of PITPa in mice results in neonatal lethality characterized by intestinal and hepatic steatosis, spinocerebellar neurodegeneration, and glucose homeostatic defects. We report that mice expressing a PITPa selectively ablated for PtdIns binding activity (Pitpa T59D
Abstract Phosphatidylinositol transfer proteins (PITPs) bind phosphatidylinositol (PtdIns) and phosphatidylcholine and play diverse roles in coordinating lipid metabolism/ signaling with intracellular functions. The underlying mechanisms remain unclear. Genetic ablation of PITPa in mice results in neonatal lethality characterized by intestinal and hepatic steatosis, spinocerebellar neurodegeneration, and glucose homeostatic defects. We report that mice expressing a PITPa selectively ablated for PtdIns binding activity (Pitpa T59D ), as the sole source of PITPa, exhibit phenotypes that recapitulate those of authentic PITPa nullizygotes. Analyses of mice with graded reductions in PITPa activity reveal proportionately graded reductions in lifespan, demonstrate that intestinal steatosis and hypoglycemia are apparent only when PITPa protein levels are strongly reduced (>90%), and correlate steatotic and glucose homeostatic defects with cerebellar inflammatory disease. Finally, reconstitution of PITPa expression in the small intestine substantially corrects the chylomicron retention disease and cerebellar inflammation of Pitpa 0/0 neonates, but does not rescue neonatal lethality in these animals. These data demonstrate that PtdIns binding is an essential functional property of PITPa in vivo, and suggest a causal linkage between defects in lipid transport and glucose homeostasis and cerebellar inflammatory disease. Finally, the data also demonstrate intrinsic neuronal deficits in PITPa-deficient mice that are independent of intestinal lipid transport defects and hypoglycemia.-Alb, J. G., Jr., S. E. Phillips The physical compartmentation of signal transduction to specific microdomains of membrane surfaces is a common property of all eukaryotic cells, and various mechanisms are applied toward achieving this end (1) (2) (3) (4) (5) . One such mechanism involves the spatially and temporally regulated metabolic channeling of phosphatidylinositol (PtdIns) and/or phosphatidylcholine (PtdCho) monomers by phosphatidylinositol transfer proteins (PITPs). This PITP-mediated channeling is itself linked to specific physiological outcomes (6) (7) (8) . Prime among these are the roles of PITPs in coordinating various interfaces between lipid metabolism and membrane trafficking reactions. PITPs fall into two unrelated structural classes: the Sec14-like PITPs and the so-called class 1 metazoan PITPs (9) (10) (11) (12) . The Sec14-like PITPs are better understood because detailed functional analyses have been more accessible for these proteins. The metazoan PITPs are poorly characterized from a functional point of view.
Mammals express four known class 1 PITP forms: PITPa, PITPb, an alternative spliceoform of PITPb, and rdgBb (13) (14) (15) (16) (17) (18) . Data that address in vivo functions for PITPa and PITPb are building. These proteins are encoded by distinct genes but are highly similar, sharing 77% and 95% primary sequence identity and similarity, respectively. The extensive homology notwithstanding, available data suggest that PITPa and PITPb execute distinct roles in mammals. First, these proteins exhibit distinct intracellular distributions. PITPa represents a cytosolic/nuclear protein, whereas PITPb is localized predominantly to the trans-Golgi network of mammalian cells [as is its alternative spliceoform (17) ]. Second, PITPb binds the ceramidebased phospholipid sphingomyelin, whereas PITPa does not (15, 17, 19) . Finally, the consequences of the genetic ablation of each protein are different (20, 21) . The functional nonredundancy of PITPa and PITPb conforms to the general theme that PITPs are tightly coupled to specific physiological functions in cells (6) (7) (8) . How PITPs couple individual PtdIns and PtdCho binding activities to biological functions remains to be determined.
Genetic ablation of the PITPa structural gene in mice has interesting consequences. Pitpa 0/0 progeny develop to term, but expire within several days after birth from a complex disease course that includes defects in dietary fat and a-tocopherol transport from the small intestine [chylomicron retention disease (CRD)], liver steatosis, hypoglycemia, inflammation of cerebellum and hindbrain, and spinocerebellar neurodegenerative disease (21) . These pathologies raise a number of questions. First, which biochemical properties of PITPa are relevant for in vivo function (i.e., are the PtdIns and PtdCho binding activities differentially used in vivo, or are these themselves coupled?). Second, which of these pathologies are causally linked, and which derive from independent insults? It is suggested the intestinal defects and hypoglycemia are linked, and that these defects provoke the cerebellar and hindbrain neurodegenerative diseases (21) . Resolution of these questions is key to an understanding of PITPa function in mammalian systems.
Here, we show that PtdIns binding is an essential functional property of PITPa in mammals. It is further demonstrated that intestinal steatosis and hypoglycemia require manifest reductions in PITPa activity, and that these pathologies correlate with cerebellar inflammatory disease. Finally, the data indicate that reconstitution of PITPa expression in the small intestine alleviates the CRD and cerebellar inflammatory disease of Pitpa 0/0 neonates, but fails to effectively rescue the neonatal lethality of these animals. This failure is accompanied by exacerbations in microvesicular steatosis of the liver, a result consistent with the idea that PITPa regulates the trafficking of luminal lipid cargos.
MATERIALS AND METHODS

Mouse genotyping
Wild-type and Pitpa::NEO alleles were diagnosed from tail clip genomic DNA templates using a three-primer PCR assay described previously (21) . To screen for the vibrator allele (Pitpa vb ), a hypomorphic mutation that reduces the expression of wildtype PITPa by ?80%, an intracisternal A particle retrotransposon three-primer PCR assay was used (22) . The allele-specific forward primers for the wild-type and vibrator alleles were HamFor (5 ¶-AGTGATCGGGACTTTTGTTTCC-3 ¶) and intracisternal A particle retrotransposon-1 (5 ¶-AACGCGTCTAATAACACTTGTG-3 ¶), respectively. A common reverse primer was used, Ham-Rev (5 ¶-CCAAAAGGACTGCCCAGTCATTTTTCCCC-3 ¶). The vibrator primer sequences were provided courtesy of Bruce Hamilton (University of California at San Diego).
To generate a PITPa transgene whose expression is limited to the duodenum, plasmid pNSE-EX4 (23) (a gift of Greg Cox, Jackson Laboratories, Bar Harbor, ME) was cleaved with XhoI to remove the existing neuronal enolase promoter, and the intestinal fatty acid binding promoter (P IFABP ) (24) was introduced in its stead. The PITP a open reading frame cDNA was generated by PCR as a 5 ¶-Hind III-EcoRI-3 ¶ fragment and correspondingly subcloned into the P IFABP -pNSE-EX4 vector to yield plasmid pFabpiPITPa. The resultant plasmid was linearized by digestion with restriction endonuclease Sal I and injected into C57BL/ 6J3C3H hybrid pronuclei at the University of North Carolina Animals Model Core to generate transgenic murine founder lines. Transgenic founders were identified with a PITP a cDNA-specific set of primers: Alpha-For (5 ¶-GCAAAGTTCCCACGTTTGTTCG-3 ¶) and Alpha-Rev (5 ¶-CTCTTGCTTATGTATAAAGTTTTCC-3 ¶). These primers support the synthesis of a diagnostic 450 bp PCR product. Three independent founders were crossed to C57BL/6J PITPa 1/0 mice to generate Pitp a 1/0
;Tg(P IFABP ::PITP a) lines.
Generation of a PtdIns binding-deficient PITPa transgene
Escherichia coli strain DY380 was transformed with P1 clone 4232 (a gift from Bruce Hamilton, University of California at San Diego), which contains the entire PITP a genomic locus in a P1 artificial chromosome (PAC) vector harboring a kanamycin resistance selection marker, to generate E. coli strain DY380-Tg(PITP a). DY380 is permissive for homologous recombination when electroporated linear double-stranded DNA is introduced into this E. coli host (25, 26) . The T59D missense substitution was incorporated into exon 3 of the PITP a gene as follows. A pair of 100mer oligonucleotides precisely complementary to each other in their respective 3 ¶ 20 nucleotides was constructed. The 20 bp complementary regions spanned the threonine 59 codon, which was converted during oligonucleotide synthesis from the wildtype ACA nucleotide sequence to GAG (and the corresponding reverse complement). Oligonucleotides were annealed at 42jC for 1 h, and the remaining 3 ¶ recessed ends were filled in with Klenow fragment of DNA polymerase I (Promega, Madison, WI). The resultant 200 bp linear double-stranded DNA fragment represented the targeting cassette for incorporating the T59D missense mutation into exon 3 of the PITP a structural gene.
The 200 bp target fragment was electroporated into DY380-Tg(PITP a) cells prechallenged at 42jC for 15 min (to induce the recombineering machinery), transformants were selected in Luria broth supplemented with kanamycin (50 mg/ml), survivors were serially diluted into five 96-well culture plates to a density of ?10 colony-forming units per well, and the individual pools were expanded. Aliquots from each well were collected and corresponding DNA templates were prepared for screening using a mismatch amplification mutation assay (MAMA) PCR. MAMA-PCR used a forward primer (5 ¶-GGCGAGAAAGGCGAGTACGAG-3 ¶) specific for the mutant T59D codon (underlined) and reverse primer (5 ¶-CTCACATGCCACACACTCC-3 ¶) that hybridizes to sequences within the PITP a gene not represented in the original 200 bp targeting fragment. Aliquots yielding a 300 bp PCR product diagnostic of Pitp a T59D clones identified the wells of interest, and the corresponding well cultures were subjected to limit dilution and plated for single colonies. Individual colonies derived from well pools of interest were rescreened by MAMA-PCR. Positive clones yielded candidate purified P1 Tg(Pitp a T59D clones. Identities were verified by nucleotide sequence analysis of PITP a exon 3 of individual candidates. We estimate a 1:12,000 ratio of Tg(Pitp a T59D ) to Tg(PITP a) in the final pools.
ELISA analyses, serial amounts of brain lysate protein for each experimental sample (1 mg, 100 ng, and 10 ng) were coated, in duplicate, on 96-well plastic plates. Samples were dried overnight, washed in 0.5% Tween 20, blocked with 2% BSA, incubated with the appropriate primary antibody overnight at room temperature, washed in PBS, incubated with secondary antibody, and finally developed using o-phenylenediamine reagent (Sigma, St. Louis, MO).
Blood chemistry
Whole blood was collected from mice immediately after decapitation or via heart puncture (in 2 mM EDTA, pH 7.2, final concentration for plasma), clotted, and clarified by low-speed centrifugation. Serum glucose was determined by the Trinder assay (Sigma). Plasma triglyceride (TG) measurements were performed on 30 ml plasma aliquots at the Animal Clinical Chemistry and Gene Expression Laboratories at the University of North Carolina-Chapel Hill. Agarose electrophoresis of whole serum used the Titan Gel Lipoprotein Kit (Helena Laboratories, Beaumont, TX) according to the manufacturer's specifications. Resolved samples were developed by staining of gels in 0.1% Fat Red 7B (w/v) in 95% methanol. Chylomicron densities were determined by scanning dried Titan gels using a Bio-Rad VersaDoc imaging system (525 nm) and quantified by the Quantity One software package.
Whole carcass analyses
Carcass compositional analyses were performed as described (21) . Briefly, eviscerated carcasses were weighed and body water content determined after drying. Dried carcasses were ground to homogeneity and extracted with petroleum ether in a Soxhlet apparatus to determine fat mass and fat-free dry mass. Carcass ash was measured after limit incineration of fat-free dry mass material.
Histological methods
Mice were prepared for all analyses by anesthesia with 1.25% Avertin (Sigma) and fixed by heart perfusion with sequential phosphate-buffered saline and 4% paraformaldehyde solutions. Intestines, brains, and livers were harvested, intestines were flushed with fixative, and all tissues were postfixed in 4% paraformaldehyde for 24 h. When dehydration was required, tissues were embedded in paraffin, and 5 mm thick sections were cut and mounted onto slides. When frozen samples were required, tissues were embedded in OCT, and 12 mm thick sections were cut and mounted.
For intestinal and liver staining with osmium (27) , paraffin sections were rehydrated in a step series starting with xylene and terminating with 50% ethanol (EtOH) (i.e., xylene, 95% EtOH, 90% EtOH, 80% EtOH, 70% EtOH, 60% EtOH, and 50% EtOH), stained for total lipid by incubation with 5% potassium dichromate and 2% OsO 4 for 8 h, and counterstained with toluidine blue O. Samples were then dehydrated in a 50% EtOH-to-xylene series that was the reverse of the rehydration series described above. Dehydrated sections were mounted in Permount (Fisher Scientific, Atlanta, GA). Oil Red O staining was used to identify neutral lipid (27) . Frozen sections mounted onto slides were incubated in 85% propylene glycol, stained with Oil Red O, counterstained with hematoxylin, and mounted in glycerol.
For whole brain analyses, fixed samples were washed for several days in phosphate-buffered saline. Brains were then sliced in half along the sagittal plane and embedded in paraffin, and 5 mm-thick sections were cut. Sections were rehydrated as described above and incubated with anti-glial fibrillary acidic protein (GFAP) antibody (EMD Biosciences CalBiochem, San Diego, CA). Decorated slices were developed with the Vectastain ABC kit (Vector Laboratories, Burlingame, CA), followed by counterstaining with toluidine blue. Samples were finally dehydrated in xylene/EtOH (50%) and mounted in Permount (Fisher Scientific).
a-Tocopherol measurements
Whole brains were harvested from decapitated mice, and atocopherol was extracted with chloroform as described (21) . Samples were resolved by HPLC using a Perkin-Elmer Life Sciences model LC200 gradient pump with an AS 200 Autosampler and an LC 295 ultraviolet-visible light detector.
Liver glycogen analysis
Whole livers were extracted from euthanized animals and homogenized, and glycogen was recovered by acid extraction (28) . Recovered material was quantitatively hydrolyzed to glucose by amyloglucosidase, and released glucose was quantified by Trinder assay (Sigma).
Hippocampal field excitatory postsynaptic potential recordings
Age-matched (P4-P6) PITP a 1/1 and Pitpa 0/0 mice were anesthetized with an overdose of pentobarbital barbiturate and decapitated upon the disappearance of corneal reflexes, in compliance with U. S. Department of Health and Human Services and University of North Carolina guidelines. Brains were dissected immediately, and dorsal hippocampi were cut in 400 mm coronal slices in ice-cold oxygenated dissection buffer (75 mM sucrose, 87 mM NaCl, 2.5 mM KCl, 1.25 mM NaH 2 PO 4 , 26 mM NaHCO 3 , 10 mM glucose, 7 mM MgCl 2 , 0.5 mM CaCl 2 , and 1.3 mM ascorbic acid). Hippocampal slices were equilibrated for 30 min in a submersion chamber at 35jC filled with artificial cerebrospinal fluid (124 mM NaCl, 3 mM KCl, 1.25 mM Na 2 PO 4 , 26 mM NaHCO 3 , 1 mM MgCl 2 , 2 mM CaCl 2 , and 20 mM Dglucose, saturated with 95% O 2 and 5% CO 2 ; ?315 mOsm and pH ? 7.25) and then held at room temperature until use. For recordings, hippocampal slices were placed in an interface chamber, maintained at 31jC, and perfused with oxygenated artificial cerebrospinal fluid. Synaptic responses were evoked by stimulating the Schaffer collaterals with a bipolar stimulating electrode (FHC, Inc., Bowdoin, ME), and field excitatory postsynaptic potentials (fEPSPs) were recorded in stratum radiatum of the CA1 region. Input-output curves were generated by systematically varying the stimulation intensity and measuring the fEPSP slope. Fiber volley amplitude was compared with the fEPSP slope to relate presynaptic to postsynaptic responses. The paired-pulse facilitation of the fEPSP slope and amplitude was examined by adjusting the stimulation intensity to the half-maximal response and systematically varying the interstimulus interval between two stimulations. Statistical analyses used a multivariate two-way ANOVA, with significance placed at P , 0.05.
RESULTS
A murine strain that exclusively expresses a PtdIns binding-deficient PITPa
PITPa binds/exchanges PtdIns and PtdCho monomers between membrane bilayers in vitro. It is not yet established what each individual activity contributes to PITPa action in cells. The availability of mutant PITPa derivatives with selective defects in PtdIns binding (29) , and the ability to generate PITPa nullizygous (Pitpa 0/0 ) mice with outstanding phenotypes (21) , permit experimental assay of the contribution of PtdIns binding to PITPa function in the mammal. To this end, the mutant Pitpa T59D was used to assess the in vivo consequences of inactivating PITPa PtdIns binding activity. Residue threonine 59 is required for coordination of the inositol headgroup of PtdIns, and the introduction of any residue bulkier than threonine at this position evokes a selective steric incompatibility with PtdIns binding (Fig. 1) (10, 29, 30) . Because choline is less bulky than inositol, PtdCho binding is unaffected in Pitpa T59D . The strategy used for generating mice that express only Pitpa T59D involved recombineering-mediated sitedirected mutagenesis of a 76 kDa PAC containing the entire PITPa genomic locus. This PAC [henceforth referred to as Tg(PITPa)] was shown previously to phenotypically complement the hypomorphic PITPa vibrator mutation (22) . As a control for all subsequent experiments, we tested whether Tg(PITPa) also rescues Pitpa 0/0 lethality. Indeed, Tg(PITPa) efficiently complements all Pitpa 0/0 -associated phenotypes. Pitpa 0/0 ;Tg(PITPa) animals are long-lived (the oldest animals are 16 months of age at present and healthy), are fertile, and are phenotypically PITPa 1/1 in all obvious respects (data not shown). Thus, the Tg(PITPa) vector is a suitable precursor for the expression of mutant forms of PITPa in the mouse for functional studies.
The PITPa PAC mutagenesis scheme is outlined in Fig. 2A . The Pitpa T59D PAC [referred to as Tg(Pitpa ) was diagnosed by probing for DNA sequences unique to the bacterial plasmid backbone of this vector ( Fig. 2B ) (see Materials and Methods). However, because an intact 76 kDa PITPa locus was used as the mutagenesis substrate, diagnostic assays for Tg(Pitpa T59D ) were more complicated. Additional methods were required to independently confirm mouse genotypes (see below). To that end, a robust MAMA-PCR strategy that distinguishes the endogenous PITPa locus from ectopic Tg(Pitpa T59D ) was developed for purposes of diagnostic genotyping of transgenic mice (see Materials and Methods) (Fig. 2B ). Demonstration that this assay reliably detects Pitpa T59D in genomic DNA preparations is shown in Fig. 2C .
That Tg(Pitpa T59D ) is transcribed was verified by two lines of evidence. First, reverse transcription PCR using the same primers used for MAMA-PCR detected Tg(Pitpa T59D ) mRNA only in Tg(Pitpa T59D ) mice (Fig. 2D) . Second, DNA sequence analysis of the entire PITPa cDNA coding sequence generated by reverse transcription of brain mRNA from PITPa ) supports transcriptional expression at levels comparable to those of endogenous PITPa.
PtdIns binding/transfer is required for PITPa function in mammals
Standard matings between PITPa 1/0 ;Tg(Pitpa T59D ) males and females generated the full complement of expected genotypes. As all PITPa-sufficient progeny exhibited phenotypes indistinguishable from the wild type, irrespective of their Tg(Pitpa T59D ) genotype, we restricted our attention to comparisons of PITPa ) progeny at P3 and P6 revealed that both strains exhibited the wasting phenotype typical of PITPa nullizygotes. This wasting was associated with dramatic reductions in the contribution of subcutaneous fat to total body mass (data not shown). Additional analyses of Pitpa 0/0 ;Tg(Pitpa T59D ) mice demonstrated that these also exhibited the striking hypoglycemia and intestinal and liver microvesicular steatosis disorders that accompany PITPa nullizygosity ( Table 1) . Phenotypic manifestations of the robust neurodegenerative disease characteristic of Pitpa 0/0 neonates were also apparent (data not shown). In sum, the Pitpa 0/0 and Pitpa 0/0 ;Tg(Pitpa T59D ) phenotypes were indistinguishable based on criteria of severity and rate of onset.
Failure of Tg(Pitpa T59D ) to rescue lethality, or the other various pathologies of Pitpa 0/0 mice, revealed an intrinsic biological nonfunctionality of Pitpa T59D . Lack of activity was not a consequence of reduced protein expression or stability. Immunoblotting for PITPa in total brain, duodenum, and liver extracts culled from appropriate mouse strains showed that Pitpa T59D levels are comparable to those of PITPa in vivo (Fig. 3C) . For final confirmation, The van der Waals space of PITPa residue threonine 59 is depicted in mesh mode (violet), whereas the van der Waals space of the inositol ring of bound PtdIns is rendered in dot mode (red and yellow). Note how closely the threonine 59 side chain abuts inositol ring space. Right panel: Same as the left panel except an aspartate side chain is modeled for threonine at PITPa residue 59 to depict the T59D missense mutation. The aspartate 59 van der Waals space is rendered in green mesh. Note the steric incompatibility between aspartate 59 and the inositol ring of PITPa-bound PtdIns. Both PITPa and Pitpa T59D images were generated with PyMOL 0.99 using the PtdIns-bound PITPa crystal structure as a framework (Protein Data Bank accession number 1UW5) (30) . ) mice (Fig. 2E, right panel) . We conclude from these experiments that PtdIns binding is essential for PITPa biological activity.
An allelic series for titrating PITPa expression in mice
PITPa-deficient mice elaborate multiple phenotypes. Manifestation of some of these phenotypes is sensitive to amounts of PITPa protein (21, 22) . These findings suggest that titration of PITPa function in mice is a viable approach for discerning relationships between the complex phenotypes that accompany PITPa insufficiencies. To this end, we took advantage of the availability of Pitpa 0 and Pitpa vb alleles to create a series of murine strains with graded levels of PITPa expression. The Pitpa vb allele reduces the expression of wild-type PITPa as a result of the insertion of an IAP element into intronic sequences of the PITPa structural gene (22) . Because the Pitpa 0 allele was originally fixed in the 129SVJ genetic background, and the hypomorphic Pitpa vb phenotype is sensitive to genetic modifiers (22) , Pitpa 0 was incorporated into the C57BL/6J genetic background by serial backcross (see Materials and Methods). The C57BL/6J background elicits the most severe phenotype for the Pitpa vb homozygote mice and is ) protein is expressed at physiological levels. Immunoblot analysis of PITPa immunoreactive species from whole brain (WBr), duodenum (Dnm), and liver, collected from P6 littermates of the indicated genotypes, using a PITPa-specific C-terminal polyclonal antibody (top panels). The bottom panels depict the corresponding blots that were stripped and reprobed with a b-actin-specific antibody for purposes of normalization.
minimized for the Pitpa vb genetic modifiers detected in other murine strain backgrounds (22 (Fig. 4A, B) . Again, in both experiments, antibodies specific for PITPa were used to avoid confounding issues presented by the highly similar PITPb isoform in these mice. In that regard, PITPa 1/1 , PITPa (Fig. 4B) . These data indicate that the titration range for PITPa was a satisfactorily broad one. For purposes of these studies, we focus on PITPa 1/1 and Pitpa 0/0 strains as positive and null controls, respectively, and Pitpa vb/vb and Pitpa vb/0 mice as experimental variables.
Phenotypes of mice with graded reductions in PITPa expression
Analyses of the allelic series emphasized the close correlation between the primary phenotypes of PITPadeficient animals and levels of PITPa expression. From the perspective of viability, Pitpa 0/0 offspring exhibited a steady mortality rate in the P0 to P11 window. Pitpa vb/0 animals survived until P19 and then expired precipitously over the next 3 days (Fig. 5A) . Similarly, and in agreement with previous reports (22, 31) juveniles were afflicted with a whole body tremor whose onset was observed at P18. This onset advanced to P12 for Pitpa vb/0 mice. Body mass analyses revealed a similar pattern. Whereas a clear distinction in mass was already apparent between PITPa 1/1 and Pitpa 0/0 littermates by P5 (3.3 6 0.4 vs. 1.9 6 0.5 g; P , 0.003) (Fig. 5B) , a significant difference between the average body mass of PITPa 1/1 and Pitpa vb/0 animals was not scored until P11 (Fig. 5B, C) . This difference in mass coincided with onset of the whole body tremor in the Pitpa vb/0 animals, and it exaggerated rapidly. By P15, Pitpa vb/0 juveniles embarked on a swift wasting process that persisted until death (Fig. 5B) .
Quantitative relationship between PITPa activity and steatosis of intestine and liver A hallmark pathology of Pitpa 0/0 neonates is a microvesicular steatosis of duodenal enterocytes and liver. The intestinal steatosis reflects the accumulation of dietary fat in enterocytes as a result of defective transport of that material from enterocytes into the circulation. These steatotic phenotypes are proposed to reflect defects in chylomicron biogenesis in enterocytes and lipid processing in the liver, respectively (21) . Steatosis is amenable to histological examination by osmium staining of thin tissue sections, and intestinal steatosis is also diagnosed by analytical measurements of postprandial plasma TGs and brain a-tocopherol. Although osmium staining of duodenal and liver tissue sections revealed the expected steatosis in Pitpa 0/0 offspring, clear reductions in enterocytic and hepatic steatosis were observed in Pitpa vb/0 siblings. No overt steatotic pathologies were apparent in Pitpa vb/vb animals relative to wild-type sibling controls (Fig. 6A, B) .
The histological data were consistent with measurements of postprandial plasma TGs and brain a-tocopherol. Regarding plasma TG content, Pitpa 0/0 neonates exhibited ?4-fold reductions in circulating plasma TG relative Serum glucose values were measured in duplicate for each mouse to give an average value, which was then used to generate the average values reported for each group. Single plasma TG measurements were taken for each mouse, and these values were then averaged to yield the data shown. Serum glucose and plasma TG measurements were performed using the same blood samples collected from each mouse. Steatosis of intestine and liver was monitored by osmium staining of organ sections collected from mice of the indicated age and genotype.
to PITPa 1/1 siblings, whereas Pitpa vb/0 mice showed only an ?2-fold reduction in the same parameter. Pitpa vb/vb offspring presented normal circulating plasma TG (Fig. 6C) . Similarly, the brain a-tocopherol deficit in Pitpa 0/0 offspring (0.69 6 0.31 vs. 2.71 6 0.45 ng/mg for PITPa 1/1 siblings) was corrected in Pitpa vb/0 and Pitpa vb/vb brain (2.60 6 0.32 and 2.51 6 0.56 ng/mg, respectively; Fig. 6D ). These data indicate that the intestinal and liver steatosis pathologies manifest themselves only in the face of large (>90%) reductions in PITPa expression.
Reconstitution of PITPa in small intestine of
The involvement of PITPa in chylomicron trafficking from nullizygous enterocytes is puzzling, as the affected organelle [endoplasmic reticulum (ER)] is the major intracellular site of lipid synthesis. Moreover, it remains unknown whether this pathology reflects a tissue-autonomous defect and what CRD contributes to the complex disease phenotypes of Pitpa 0/0 neonates. To this end, a transgene was engineered in which duodenum-specific expression of PITPa cDNA is driven by the intestinal fatty acid binding protein enhancer [Tg(P IFABP ::PITPa)] (Fig. 7A) , Pitpa 0/0 , and Pitpa 0/0 ;Tg(P IFABP ::PITPa) offspring confirmed that the transgene supports a satisfactory tissue-specific expression of physiologically relevant levels of PITPa (Fig. 7A) .
Osmium staining demonstrated that Pitpa 0/0 ;Tg(P IFABP :: PITPa) offspring were relieved of the intestinal steatosis observed for their Pitpa 0/0 siblings (Fig. 7B) . The rescueof-steatosis phenotype exhibited tissue specificity, as liver steatosis was not alleviated by Tg(P IFABP ::PITPa) (Fig. 7C) . In fact, this liver pathology was, if anything, exacerbated. Thin-section electron microscopy confirmed this effect and indicated that the accumulated lipid in Pitpa 0/0 ; Tg(P IFABP ::PITPa) liver is divided between what appears to be a pool that resides in the ER lumen and a pool that partitions into cytoplasmic lipid droplets (data not shown). Rescue of intestinal steatosis, as scored by histological staining methods, was accompanied by improved transport of chylomicron into the circulation. Pitpa 0/0 ;Tg(P IFABP ::PITPa) animals exhibited 59.1 6 10.6% of the serum chylomicron load of their age-matched PITPa 1/1 controls. Relative to Pitpa 0/0 animals, whose circulating chylomicron load was just 24.7 6 8.8% of wild-type levels (Fig. 8A) , this represented a marked improvement.
Plasma TG and brain a-tocopherol enter the circulation via the chylomicron pathway, and measurements of these components were congruent with the chylomicron data. Pitpa 0/0 ;Tg(P IFABP ::PITPa) neonates exhibited 59.2 6 5.9 mg/dl relative to 39.2 6 6.1 and 138.1 6 7.9 mg/dl plasma TG for Pitpa 0/0 and PITPa 1/1 siblings, respectively (Fig. 8B) . Substantial rescue of brain a-tocopherol deficit was similarly registered in Pitpa 0/0 ;Tg(P IFABP ::PITPa) offspring (3.04 6 0.72 vs. 1.19 6 0.22 and 3.99 6 0.68 ng/mg brain tissue for Pitpa 0/0 and PITPa 1/1 littermates, respectively; Fig. 8C ). Thus, intestinal steatosis is a tissueautonomous pathology in Pitpa 0/0 mice. Lifespan and body mass measurements indicated that duodenal PITPa expression levied modest improvement in these parameters relative to Pitpa 0/0 siblings. Although ?75% of the Pitpa 0/0 offspring expired within the first 3 days after birth, some 80% of their Pitpa 0/0 ;Tg(P IFABP :: PITPa) siblings survived past this benchmark (Fig. 9A) . A 75% mortality standard was not reached for the Pitpa 0/0 ; Tg(P IFABP ::PITPa) neonates until ?8 days after birth. Again, although modest, this represents an effective doubling of the Pitpa 0/0 lifespan. Body mass measurements also showed measurable increases in weight gain differential for Pitpa 0/0 ;Tg(P IFABP ::PITPa) and Pitpa 0/0 neonates (Fig. 9B ). For instance, at P7, the respective mass differential was 3.1 6 0.3 versus 2.3 6 0.5 g (P 5 0.026).
PITPa expression and glucose homeostasis
Pitpa 0/0 neonates are hypoglycemic. This condition is suggested to contribute to the neurodegenerative pathologies and morbidity of mutant animals. Hypoglycemia coincides with pancreatic islet defects, reduced proglucagon expression, and inefficient glycogenolysis (21) . Consistent with previous findings, serum glucose was reduced by ?4-fold for Pitpa 0/0 neonates compared with wild-type littermate controls (2.0 6 0.1 vs. 8.3 6 0.2 mM; Fig. 10A ). By contrast, Pitpa vb/0 neonates exhibited serum glucose levels that were 2.8-fold higher than those of Pitp 0/0 mice (Fig. 10A ). This increase was accompanied by the restoration of efficient glycogenolysis in Pitpa vb/0 animals (data not shown). Although an improvement, those levels were still ?2-fold lower than those of PITPa Fig. 10A ). Thus, as was found for the microvesicular steatosis of duodenum and liver, hypoglycemias associated with PITPa defects require manifest reductions in PITPa activity (>90%). Specific reconstitution of PITPa expression in the duodenum of Pitpa 0/0 animals [Pitpa 0/0 ;Tg(P IFABP ::PITPa)] also led to an increase in serum glucose, but this too was incomplete. Circulating glucose values approached, but did not meet, those measured for Pitpa vb/0 mice (3.5 6 0.1 vs. 5.6 6 0.8 mM; Fig. 10A ). Analyses of serum glucose as a function of age were also informative. All neonates, re- animals rapidly overcame this condition, Pitpa 0/0 progeny did not (Fig. 10B) . Pitpa vb/0 and Pitpa 0/0 ;Tg(P IFABP ::PITPa) neonates exhibited intermediate increases in serum glucose with age but failed to meet the levels measured for PITPa 1/1 and Pitpa vb/vb animals.
PITPa expression and cerebellar neurodegeneration
A hallmark phenotype of Pitpa 0/0 mice is a robust hindbrain and cerebellar inflammatory disease characterized by reactive gliosis in these tissues (21) . This pathology is scored by staining for GFAP, a marker for activated astrocytes (Fig. 11A) . It is suggested that the Pitpa 0/0 cerebellum is particularly sensitive to damage wrought by a systemic energy crisis, such as that precipitated by the CRD and hypoglycemia of Pitpa 0/0 neonates (21). Consistent with this proposal, cerebellar inflammatory disease was substantially alleviated in both Pitpa vb/vb and Pitpa 0/0 ;Tg(P IFABP ::PITPa) neonates, as indicated by dramatic reductions in GFAPpositive cells in tissue derived from those mice. By contrast, hindbrain inflammation was not alleviated in either Pitpa 0/0 ;Tg(P IFABP ::PITPa) or Pitpa vb/0 neonates (Fig. 11B) . The persistent hindbrain inflammation presumably reflects some intrinsic fragility/deficit in Pitpa 0/0 hindbrain neurons.
PITPa nullizygosity and efficacy of synaptic transmission
Phosphoinositide signaling plays integral roles in regulating neuronal membrane trafficking (32, 33) . This raised the possibility that PITPa regulates the synaptic cycle and that the neurodegenerative disorder of Pitpa 0/0 mice may reflect central deficits in synaptic vesicle release and neurotransmission. To address this issue, basic properties of synaptic transmission in the CA1 region of the hippocampus were examined. The experimental model was justified by two criteria. First, synaptic transmission in the hippocampus is experimentally well characterized. Second, PITPa is highly expressed in hippocampus, as indicated by LacZ "knock-in" studies using a Pitpa::neo/puro/LacZ splice-trap allele (20) . b-Galactosidase staining of P10 PITPa 1 / Pitpa::neo/ puro/LacZ brain sections revealed robust PITPa expression in the hippocampus (Fig. 12A) .
To compare basal synaptic strengths, age-matched PITPa 1/1 and Pitpa 0/0 mice were used to facilitate hippocampal recordings. In these experiments, input-output curves were generated by varying the stimulation intensity of the Schaffer collateral inputs and recording the slope of the fEPSP. The data indicate that basal synaptic strengths were similar between PITPa 1/1 and Pitpa 0/0 mice ( Fig. 12B ; P 5 0.949). To ensure that the relationship between presynaptic neurotransmitter release and the postsynaptic response was unchanged, the amplitudes of the fiber volley (a gauge for presynaptic release) were compared with the fEPSP slope (a gauge for synaptic response magnitude). There were no significant differences between PITPa 1/1 and Pitpa 0/0 mice ( Fig. 12C ; P 5 0.26), suggesting that the relationship between presynaptic release and the postsynaptic response was preserved in Pitpa 0/0 animals. To test whether the disruption of normal PITPa activity might alter the probability of presynaptic release and/or the degree of synaptic vesicle mobilization, paired-pulse facilitations across a range of interstimulus intervals were examined. Facilitation did not differ between PITPa 1/1 and Pitpa 0/0 mice, as evaluated from fEPSP slopes ( Fig. 12D ; P 5 0.35) or amplitudes ( Fig. 12E ; P 5 0.81). These data indicate that mutant CA1 synapses exhibit normal probabilities of neurotransmitter release and normal magnitudes of basal synaptic transmission. Presynaptic terminals of stratum radiatum neurons were also examined by quantitative morphometry. Defects in the synaptic vesicle cycle should result in abnormal synaptic vesicle densities in such presynaptic terminals. PITPa 1/1 and Pitpa 0/0 littermate mice (four each) were perfused with mixed aldehydes, and brains were collected and embedded. Embedded brains were sectioned through the hippocampus, further processed, and flat-embedded in plastic (34) . Blindly coded sample blocks were prepared from the CA1 region of hippocampus, and morphometric analyses focused on synapses in the stratum radiatum. A total of 117 images of randomly selected ter- , and Pitpa vb/vb animals, were harvested and corresponding extracts were assayed for atocopherol. Measurement averages with SD are shown. Genotypes are listed at bottom. minals with recognizable synapses were collected, 59 from PITPa 1/1 animals and 58 from Pitpa 0/0 mice. For each terminal, vesicles were counted within a 0.2 mm square area: 0.1 mm lateral to each side from the center of the opposing postsynaptic density and 0.2 mm back into the terminal. The number of vesicles per examined area ranged from 0 to 19. The PITPa 1/1 and Pitpa 0/0 mice averaged 6.4 and 7.7 vesicles per synapse, respectively. Although there were the expected variations in the numbers of vesicles per synapse, no obvious correlation between vesicle number and PITPa status was discerned. Thus, the collective electrophysiological and morphometric data indicate that the synaptic vesicle cycle of Pitpa 0/0 mice is unperturbed, and that neurodegeneration is unlikely to be a consequence of deficits in synaptic transmission.
DISCUSSION
Here, we report a detailed analysis of PITPa function in mice. These studies take advantage of transgenic approaches to achieve three purposes. First, the contribution of PtdIns binding to PITPa function in vivo was evaluated. Second, a series of isogenic mouse strains with graded reductions in PITPa activity was analyzed to examine the relationships between the complex pathologies apparent in Pitpa 0/0 neonates. Third, the consequences of reconstituting PITPa expression solely in the small intestine of Pitpa 0/0 animals were assessed. The conclusions derived from these analyses are as follows: i) PtdIns binding activity is essential for PITPa function in the mouse; ii) the lifespan of neonatal and juvenile mice is highly sensitive to levels of PITPa; iii) large reductions in PITPa expression are required for the elaboration of intestinal and liver steatotic phenotypes and hypoglycemia; iv) intestinal steatosis is a tissue-autonomous pathology that is rescued by tissue-specific expression of PITPa; v) hindbrain neurodegenerative processes can be largely uncoupled from intestinal/liver steatosis and hypoglycemia, whereas cerebellar inflammatory disease cannot; and vi) elimination of PITPa activity has no apparent consequence for synaptic efficacy, even in neurons that normally exhibit high levels of PITPa expression. Together, these data provide the first in vivo demonstration of a meaningful biological role for PtdIns binding by PITPa. The data also bolster the idea that PITPa plays a role in the biogenesis and transport of lipid/ lipoprotein cargo from intracellular organelles.
PtdIns binding and PITPa function
Current models suggest that PITPa is devoted primarily to phosphoinositide synthesis, particularly PtdIns-4,5-P 2 synthesis (35) (36) (37) (38) . Such a role could involve a direct coupling between PITPa and PtdIns 4-OH kinases, in which PITPa presents PtdIns to the enzyme and thereby potentiates its catalytic activity. A more indirect PtdIns delivery mechanism, in which PITPa supplies PtdIns to sites of active signaling from other intracellular membranes (e.g., by PtdIns transfer), is also plausible. Alternatively, PITPa could stimulate PtdIns-4,5-P 2 synthesis by potentiating phospholipase D-mediated hydrolysis of PtdCho [and subsequently stimulating PtdIns-4-phosphate 5-OH kinase activity via the production of the phosphatidic acid hydrolytic product (39) ]. The former two models predict a critical role for PtdIns binding by PITPa, whereas the latter model emphasizes PtdCho binding. The finding that physiological levels of expression of Pitpa 
Phenotypic consequences of graded reductions in PITPa expression
Pitpa 0/0 mice experience a complex disease course of intestinal and hepatic steatosis, hypoglycemia, and inefficient glycogenolysis (stemming from pancreatic insufficiency) and a fulminating spinocerebellar neurodegenerative disease. The neurodegeneration is marked by reactive gliosis of the cerebellum and hindbrain and aponecrotic pathologies in the spinal cord (21) . The relationships between these various pathologies is not obvious, however. Analyses of isogenic mouse lines with graded reductions in PITPa expression clarify some of these relationships. First, it is clear that the hindbrain inflammatory and spinal cord neurodegenerative diseases are intrinsic pathologies of PITPa-insufficient mice, as these can be uncoupled from intestinal/liver steatosis and hypoglycemia. This is most apparent in the case of Pitpa vb/vb mice, which express ?20% of wild-type levels of PITPa activity. Pitpa vb/vb animals suffer from both hindbrain and spinal cord neurodegeneration (22, 31) but fail to exhibit any symptoms of overt intestinal/liver steatosis or hypoglycemia. By contrast, both intestinal/liver steatosis and hypoglycemia are apparent only in mice in which PITPa activity is reduced by >90% (i.e., Pitpa 0/0 and Pitpa vb/0 lines). Moreover, the severities of the respective pathologies are closely correlated. Pitpa vb/0 mice exhibit a less severe intestinal/liver steatosis than Pitpa 0/0 siblings. Pitpa vb/0 mice also show a significantly reduced hypoglycemia. These data are consistent with the view that the hypoglycemia of PITPainsufficient mice is secondary to intestinal/hepatic lipid transport defects. ) mice in the P3-P8 time window (2.3 6 0.5 vs. 3.8 6 0.6 mM, respectively), and these differences were significant (P , 0.0002).
Dissection of PITPa function in mice
Reconstitution of PITPa expression in small intestine
The intestinal steatosis of Pitpa 0/0 mice is an intriguing phenotype. Its characteristics are consistent with a defect in the biogenesis/transport of chylomicrons from the enterocyte ER (21) . Indeed, the steatotic condition (and its consequences) resemble those of human CRD (40, 41) . One underlying mechanism for human CRD stems from defects in a specific isoform of the Sar1-GTPase (42) . This raises the attractive possibility that specific components of the COPII ER vesicle-budding machinery are dedicated to the biogenesis of vesicles containing atypical cargo, such as chylomicrons.
A role for PITPa in chylomicron biogenesis/trafficking is unanticipated, as it is not obvious why such a protein would be required for ER transport processes, given that the ER is the major site of lipid synthesis in cells. Moreover, the ER is not an acknowledged site of phosphoinositide signaling. Yet, the available data indicate a connection between PITPa function and chylomicron metabolism. Specific defects in PITPa PtdIns binding are sufficient to elicit CRD-like symptoms in Pitpa T59D -expressing mice. Moreover, reexpression of PITPa in the small intestine of Pitpa 0/0 mice alleviates the steatotic phenotype of this organ and partially rescues the biochemical defects associated with CRD. Pitpa 0/0 ;Tg(P IFABP ::PITPa) neonates also exhibit increased plasma TG levels, increases in the quantities of circulating chylomicrons, and increased brain a-tocopherol levels (a vitamin whose transport into the circulation is dependent on the chylomicron pathway) relative to Pitpa 0/0 controls. The rescue experiment additionally identifies the intestinal steatosis as a tissueautonomous pathology in Pitpa 0/0 mice. Although reconstitution of PITPa expression in the small intestine does have discernible effects, it nonetheless supports only a modest rescue of plasma TG deficits and hypoglycemia and only modest increases in the lifespan of transgenic Pitpa 0/0 animals. Exacerbated liver steatosis is observed in these mice, however. As chylomicron remnants are taken up by the liver, remodeled, and reexported as VLDL particles, we suggest that defects in lipoprotein processing/biogenesis in Pitpa 0/0 liver significantly neutralize the benefits realized by rescue of the intestinal steatosis. These data suggest a role for PITPa in the hepatic lipoprotein biogenesis/transport pathway, a reasonable possibility given that the pathways for lipoprotein biogenesis and transport are similar in the small intestine and the liver (43) (44) (45) . We predict that reconstitution of PITPa expression in both the small intestine and the liver of a Pitpa 0/0 mouse will yield what is a symptomatically Pitpa vb/vb mouse.
Differential causes of neurodegenerative disease
It was previously proposed that neonatal Pitpa 0/0 cerebellum is especially susceptible to injury because its program of robust cell proliferation is incompatible with the hypoglycemic environment presented by the nullizygous mouse (21) . The results reported here are consistent with this idea. Both Pitpa vb/0 and Pitpa 0/0 ;Tg(P IFABP ::PITPa) neonates are substantially free of the dramatic reactive gliosis that characterizes their Pitpa 0/0 siblings. This is a telling result in the context of the Pitpa 0/0 ;Tg(P IFABP ::PITPa) mouse, as the cerebellum fails to express PITPa yet is spared the normal course of inflammatory disease by PITPa expression in the small intestine. Consistent with these data, cerebellar granule cells cultured from PITPa 1/1 and Pitpa 0/0 neonates show no obvious differences in vigor when cultured in vitro (i.e., under culture conditions in which defects associated with systemic lipid transport and hypoglycemia are irrelevant; data not shown).
As hindbrain and spinal cord defects are not alleviated by PITPa expression in the duodenum, these pathologies reflect intrinsic neuronal defects of PITPa-insufficient mice. These pathologies do not stem from deficiencies in the synaptic vesicle cycle, given that synaptic function is not adversely affected by genetic ablation of PITPa activity in hippocampal neurons. Whether these intrinsic defects reflect improper neuronal development and defects in proper path finding (46) or some other signaling defect(s) remains to be determined. 
